Foundation Accredited Independent Mark of Efficacy (AIME TM ) - - PowerPoint PPT Presentation

National Health Science Foundation

Accredited Independent Mark of Efficacy (AIMETM) Session 2

RATIONALE FOR RECOGNITION OF CLINICALLY PROVEN PRODUCTS

“Many stakeholders believe in the need to provide an independent review of products to accredit those which have robust specific evidence to support them”

Options for Consumer Information Source Development by the NHSF

Recommended

What is the AIME Service?

• It is an independent way of providing consumers with the ability to

understand whether the clinical claims made for product they are buying has been supported by clinical evidence

• It provides both an on-pack logo and an online support mechanism
• There is a limited database of information about the product (containing

basic product summary information, but not an extensive database)

• Application for inclusion is made by the company marketing the product

(and in some cases by the ingredient manufacturer)and is controlled through a strict system linked through bar coding)

• The review of the application by an independent panel (the Clinical

Advisory Board – which is distinct from the Clinical Round Table)

• The service will be revenue neutral or revenue positive for the NHSF
• Both the NHSF and member companies will commit to the promotion of

the Service to ensure it becomes recognised as a mark of product excellence

• The Panel will also be able to offer advice to companies with an interest

in improving the quality of the their clinical trials with a view to improved chance of publication in preferred journals

Rationale

• The clear identification of the point of

differentiation of the well developed products in the industry will provide a clear rationale for being a part of the

• rganisation
• It will start to focus consumer awareness on

the standard they should be seeking

• It will be self funding and provide funds to

promote both the service and the

• rganisation in its formative years
• It provides a visible means of highlighting

product excellence and is a critical means

• f raising the bar for all players
• The detailed database solutions, either

alone or with the ABC continue to be important but given the limited resources of the organisation the early efforts need to focus on the activities that will provide the widest interest.

• The next stage of database development

should be considered at approximately Year 3-4of the organisations operational life

Initial Recommendation

HOW DOES IT WORK

The Assessed Independent Mark of Efficacy

What does the AIME Service Do and How does it Work

On Pack “Tick”

Denoting Levels of Evidence Facility to accommodate high Quality Ingredient Sources Equivalent Products ? TBC

Clinical Trials Review Services

Pre-Trial review service to assist companies to ensure that their trial design is robust and will provide a meaning answer to the question they are posing, and will meet the standard of well recognised peer reviewed journals Post trial review of results

• Administered by the NHSF

Secretariat

• All product inclusion

recommendations are completely at the discretion of the Independent Advisory Board

• The Advisory board is made up of

Global experts in the development and assessment of clinical evidence

• Costs associated with the

Advisory Committee are covered by the assessment fees

• The NHSF and Member

Companies commit to the promotion of the “Tick” and the Clinical Trials Advisory service

Clinical Advisory Board

• The Clinical Advisory Board (CAB)is a group of 6 independent

experts with global recognition in their area of specialty and with a proven track record in successful clinical trial development and assessment, a strong list of publications, and editorial experience on a range of peer reviewed clinical journals

• The role of the CAB is:

– To determine the criteria for product inclusion in the AIME – Review all applications for product inclusion into the AIME and approve / reject and assign status – Sign off on final documentation posted on the AIME – CAB Chair to advise the CEO of key issues, opportunities for improvement and concerns pertaining to the AIME; and to provide advice to the Board as required – The CAB Chair is not a member of the Board of Directors

Proposed CAB Membership

• Chair Professor John Funder AC MD BS PhD FRACP FRCP LLD (Hon Monash University),

DMedSci (Hon University of Melbourne), MD (Hon. University of Sydney)

– Chair of NICM Advisory Board; Member of NICM Research Committee – John Funder was President of the Australian Society for Medical Research (1979)and the Endocrine Society of Australia (1984), and (1996–2000) Chairman of the International Society for Endocrinology. In 1990 he resigned as a Senior Research Fellow of the National Health and Medical Research Council to become Director of the Baker Medical Research Institute (1990–2001). He is a Senior Fellow at Prince Henry's Institute of Medical Research at Monash Medical Centre, and a Professorial Fellow at the Centre for Neuroscience at the University of Melbourne. Having published over 500 scientific papers, Funder is an expert in mineralocorticoid receptors and aldosterone biology and serves as a consultant to many pharmaceutical companies engaged in this field.

• Dr. Gerry Bodeker researches and advises on international public policy on traditional

(indigenous), complementary & alternative medicine and wellness.

– Having completed Doctoral studies at Harvard, he has held research and teaching appointments in the Division of Medical Sciences at Oxford University for two decades. Dr. Bodeker has been chair of the Commonwealth Working Group on Traditional & Complementary Medicine and done work on medicinal plant conservation for the World Bank, the Global Environment Facility, UNU, and the UN Food & Agriculture Organization. He is co-founder of the WHO-affiliated Research Initiative on Traditional Antimalarial Methods (RITAM). He has written extensively on traditional medicine and is editor-in-chief of the WHO Global Atlas on Traditional and Complementary Medicine and serves on the editorial boards of several journals. He has authored chapters in the Encyclopedia of Public Health (Elsevier 2008, 2017) on "The health of indigenous peoples" and on "Integrative medicine".. He is a Fellow of the International Union of Pure & Applied Chemistry

Proposed CAB Membership

• Continued
• Sir Peter David Gluckman, ONZ, KNZM, FRS, FMedSci, FRSNZ is a New Zealand
• paediatrician. He is currently the inaugural Chief Science Advisor to the New Zealand

Prime Minister.

• Associate Professor David Eisenberg - Associate Professor of Nutrition at Harvard T.H. Chan

School of Public Health and Executive Vice President for Health Research and Education at the Samueli Institute.. From 2000-2010, Eisenberg served as the founding Director of the Osher Research Center at Harvard Medical School and the founding Chief of the Division for Research and Education in Complementary and Integrative Medical Therapies. He simultaneously served as the Director of the Program in Integrative Medicine at the Brigham & Women’s Hospital. His current educational and research interests include: (1) studies to assess the safety, clinical, and cost effectiveness of complementary and integrative medical therapies; (2) the systematic evaluation of herbal medicines using state of the science technologies; and (3) novel multi-disciplinary strategies to optimize lifestyle and self-care behaviors (e.g., diet, exercise and stress management) to prevent, treat and manage common medical conditions. Eisenberg is a graduate of Harvard College and Harvard Medical School. He completed his fellowship training in general internal medicine and primary care and is Board Certified in Internal Medicine. Eisenberg has served as an advisor to the National Institutes of Health, the Food and Drug Administration, and the Federation of State Medical Boards with regard to complementary, alternative and integrative medicine research, education, and policy.

Proposed CAB Membership

• Continued
• Salvador Cañigueral PhD, Professor of Pharmacognosy and Phytotherapy in the Faculty
• f Pharmacy of the University of Barcelona.

– His research deals with the chemistry and biological activity of medicinal plants.. His research also dealls with the development of methods for quality control of herbal preparations for medicines, dietary supplements, feed and cosmetics.He is widely published with over 100 research papers, 250 confernce contributions and editorship and contributions to many books. In addition, he is founder and scientific editor of the Spanish Revista de Fitoterapia and member of the editorial advisory board of the journal Planta Medica. – He is full member of the Royal Academy of Pharmacy of Catalonia, founder member and President of the Spanish Society of Phytotherapy (Sociedad Española de Fitoterapia, SEFIT), and member of the Board of the International Council for Medicinal and Aromatic Plants (ICMAP). He has also been member of the European Scientific Cooperative on Phytotherapy (ESCOP) (2003-2016) and the Board of Directors de la Society for Medicinal Plant Research (GA) (2004-2005), and the chairman of the 50th Annual Congress of the Society for Medicinal Plant Research (Barcelona, 2002). – He has been the chairman (1997-2002) of the Phytotherapy group of the Spanish National Formulary and he is the chairman (1999-) of the Phytochemistry group of the Spanish Pharmacopoeia, as well as member of the Phytochemistry groups 13A (2005-) and 13B (1999-), as well the group on Extracts (2012-), of the European Pharmacopoeia. He is the current president (2011-) of the group 13A of the European Pharmacopoeia. Additionally, he is member of the essential oil committee of the Spanish Agency of Standardisation (AENOR) and the external expert panel of EMA (European Medicines Agency).

• Additional Expert to be identified

On-Pack “Tick” for Products with their own Clinical Trials

• Early stage of product development, on the market

but with only one promising trial and a commitment to an ongoing program

• Classification valid no longer than 2 years, at which time

new data should be presented for reclassification

• Suited to start up companies with 1 0r 2 products
• One RCT showing non-inferiority published in a

peer reviewed journal

• Two or more RCTs published in well

recognised peer reviewed journals showing consistent results

Tick Process for Ingredient Companies

• Ingredient Companies may wish to apply for “Tick” status for their specific

ingredients if they have invested in clinical trials showing the effectiveness

• f their ingredient.

– They will follow the standard application process, but will receive an “Ingredient Approval” – An ingredient approval does not provide automatic on-pack access

• Products using these ingredients will then be eligible for a simplified

application process if they wish to reference the credentials of the ingredient

– Each Product that uses that ingredient must make a separate application to utilise the “Tick” on their packaging and to be listed on the database – The Application for use of an ingredient tick is a simplified process that focuses

• n the product labelling, the formulation and the recommended dosing to

ensure consistency with the original published studies – The formulation must not include ingredients that were not present in the

• riginal studies

– If the Advisory Board deem that the use of the ingredient within the product is consistent with the original trials a Linked Master Number will be provided for

• n pack artwork and the bar code will be linked to the Master Number

assigned to the ingredient in the database and the clinical information available will be consistent with that approved from the ingredient application

Tick Process for Ingredient Companies

Product “Tick” Review Process & Responsibilities

“Tick” Approval – Marketed Products

Annual Renewal

Renewal Form is sent out annually and companies advise of any changes to product or product information over the past year. Renewal is processed, or if changes have occurred (eg new clinical data, formulation change etc) , a supplementary application may be required

Database Entry

Key Summary product data sheet is signed off by advisory committee and posted to website Bar-code Link takes consumers direct from pack to Database Entry via mobile phone

“Tick” Approval is Granted

A Master Number is Generated and On-Pack logo with number is generated and pack artwork work with Logo is approved The Master Number is Linked to the Product Bar Code

Cost Estimates for Clinical Advisory Board

Core Activity Guiding Assumptions and details Total Cost $US

Clinical Advisory Board Honoraria Per diem $US2500.00 and 6 panel members Assume 1 face to face meeting per year, per diem of 3 days for all delegate, plus additional 2 days for chair (19 days) Assume 2 additional meetings with per diem average of 2 days per meeting including prep time. (The meeting is expected to be telecon

• f about 4 hours) (24 days); Plus 2 additional days through the year

for added input by Chair (2 days) Total 45 days at $US 2500 $112,500 Air travel – Clinical Advisory Board Assume business class travel for all flights over 6 hours. Meetings will be held at the most economical location. This assumes a face to face meetings in US or Europe 2 x $10,000 -$15,000 fare from Southern Hemisphere 2 x $5,000 - $7,000 fares Plus economy fares for other delegates, staff, and any other adhoc travel required by the CAB during the year $60,000 Meeting Costs Accommodation, meals, meeting room costs, telecom charges, courriers and other administrative costs $40,000 Contingency For additional CAB input, etc $37,500 Total Allowance $250,000

Clinical Trials Advisory Service

Pre- Trial Advice

• The Advisory Board will provide

advice to Member companies

• n request to review proposed

clinical protocols to ensure the best possible chance of meaningful results and publication in a respected journal.

• The service will be subject to

quote, and will be based on the number of experts involved, and the amount of time required.

• It is a service to Member

companies and will be priced on a cost recovery basis

Post- Trial Advice

• The Advisory board will also offer

the service of reviewing the analysis of clinical trials post trial to assist companies present their data in the most appropriate manner to achieve publication is a well rated journal

• Members of the Advisory Board

are well experienced with publication in peer review journals and are regularly sought after as reviewers

Recommendations

• Recommendation 1: Proceed with the development of the

concept of the AIME efficacy mark. Continue to monitor the need for and the optimal timing of the development of a broader Database solution with a target timing of year 3- year 4.

• Recommendation 2: Proceed with the appointment of the

CAB and support the first meeting of the group to take place at the earliest convenience post appointment of the CEO.